By Sabela OjeaShares of MoonLake Immunotherapeutics climbed after the company said it received positive 24-week results from a trial to treat patients with a chronic inflammatory skin condition. The stock was up 13% Monday at $61.83. The clinical-stage biopharmaceutical company said its phase 2 Mira trial showed that maintenance treatment with its sonelokimab treatment led to further improvements in patients with moderate-to-severe hidradenitis suppurativa. MoonLake Chief Executive Jorge Santos da Silva said the company is on track to discuss its phase 3 development plans with the Food and Drug Administration by the end of the year. Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix(END) Dow Jones Newswires10-16-23 1220ET

Source: Wall Street Journal October 16, 2023 22:23 UTC